natural killer cell therapy

Nkarta goes back to basics
EP Vantage
Tue, 06/27/23 - 10:07 am
Nkarta Therapeutics
natural killer cell therapy
NKX101
SPACs back from brink with NK cell therapy biotech's plans for blank-check merger
Fierce Biotech
Fri, 03/24/23 - 10:12 am
SPACs
natural killer cell therapy
NKGen
cell therapy
Editas, in next restructuring step, to sell cell therapy work to Shoreline
BioPharma Dive
Thu, 01/19/23 - 07:43 pm
Editas Medicine
natural killer cell therapy
Shoreline Biosciences
Gamida doses first subject in Phase I/II cell therapy trial for lymphomas
Clinical Trials Arena
Thu, 08/11/22 - 12:17 pm
Gamida Cell
natural killer cell therapy
GDA-201
diffuse large B-cell lymphoma
follicular B-cell non-Hodgkin lymphoma
Intellia follows CRISPR peers with deal to explore 'natural killer' cell therapy
BioPharma Dive
Tue, 02/15/22 - 11:28 pm
Intellia Therapeutics
ONK Therapeutics
natural killer cell therapy
immunotherapy
Affimed spurs promising response numbers in NK cell study, but durability will be the big question
Endpoints
Mon, 11/22/21 - 10:33 am
Affimed
natural killer cell therapy
lymphoma
Artiva, fresh from Merck pact, raises $120M for NK therapy R&D
Fierce Biotech
Mon, 03/1/21 - 10:39 am
Artiva
natural killer cell therapy
Merck
R&D
Can we freeze them? Yes we can, says Nkarta
EP Vantage
Mon, 02/15/21 - 10:26 am
NK cells
natural killer cell therapy
Nkarta Therapeutics
FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting
Endpoints
Fri, 01/8/21 - 09:34 am
Neoleukin
NL-201
FDA
natural killer cell therapy
oncology
clinical trials
Sanofi inks $358M Kiadis takeover to acquire NK-cell platform
Fierce Biotech
Mon, 11/2/20 - 10:48 am
Sanofi
Kiadis
M&A
Sarclisa
natural killer cell therapy
Natural killer biotech Artiva launches with $78M, industry veterans
Fierce Biotech
Fri, 06/26/20 - 09:50 am
immuno-oncology
natural killer cell therapy
Artiva
MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner
Endpoints
Thu, 02/6/20 - 11:50 am
Takeda
MD Anderson
natural killer cell therapy
CAR-T
Sorrento Therapeutics and Celularity Aim to Adapt Natural Killer Cell Therapy to Treat Coronavirus
Motley Fool
Thu, 01/30/20 - 10:47 am
Sorrento Therapeutics
Celularity
natural killer cell therapy
cell therapy
coronaviruses
Wuhan Coronavirus